Another lncRNA, HCG18, was identified as a promising candidate biomarker in differentiating NAFLD patients from healthy individuals (AUC = 0.934, sensitivity: 82.8%, and specificity: 89.1%) [35]. This evidence concerns the gene HCG18 and metabolic dysfunction-associated steatotic liver disease.